Incyte Ends Jakafi Pancreatic Cancer Trials, But Has More Irons In The Fire
This article was originally published in The Pink Sheet Daily
Pancreatic trial failure means the end of the inflammation hypothesis for Jakafi and thus the end of related solid tumor trials, but trials of JAK inhibitors in other solid tumors still have potential, says Incyte.
You may also be interested in...
The JAK1/2 inhibitor may add an indication for acute graft-versus-host disease, though based on a single, open-label Phase II trial that showed a 55% response rate in a high-mortality indication.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.